Video Highlights
1:11 Gary Spinner, DMSc, PA, MPH, AAHIVS
3:46 Randy Matthews, PhD, MD
4:52 Carl Schmid
|Videos|November 24, 2021
The Long-Term Prognosis of PrEP
Author(s)John Parkinson
HIV Stakeholders weigh on the future of PrEP.
Advertisement
Welcome to our series, 1 Big Question, which asks 1 question to the medical community and we get their feedback on an important infectious disease topic.
In this episode, our 1 Big Question is: Will PrEP have a prominent role and significant impact in HIV prevention?
We interviewed Gary Spinner, DMSc, PA, MPH, AAHIVS, medical director of the HIV/AIDS Program, Southwest Community Health Center, Randy Matthews, PhD, MD, senior principal scientist, Merck, and Carl Schmid, executive director, HIV+Hepatitis Policy Institute.
Check out our video to hear their insights.
Advertisement
Related to this article
Li Tao, PhD, discusses early US uptake of twice-yearly lenacapavir, faster prescription-to-injection timelines, and how ACA coverage milestones tracked with zero cost sharing and HIV diagnoses.
Dr. Reddy’s generic twice-yearly lenacapavir received FDA tentative approval for HIV PrEP. It is expected to cost $40 a year in 120 low- and middle-income countries (LMICs), with first supplies due by the end of 2026.
Jean van Wyk, MBChB, MFPM, discussed the 5-year OPERA data from IDWeek 2026 as well as the anticipated CROWN study results.
Cefiderocol MICs fell against Pseudomonas aeruginosa and Klebsiella pneumoniae, and the drug showed marked synergy with LL-37 against resistant Acinetobacter baumannii. Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses her team's findings around this therapy and these pathogens.
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Investigational asuptegravir cut HIV-1 RNA by up to 2.36 log10 copies/mL in 10 days, and adding fostemsavir boosted CD4 gains in immunologic nonresponders.
Advertisement
Advertisement
Trending on Contagion Live
1
Ebola Update: DRC Outbreak Tops 10,000 Cases as Kenya, Nigeria Report Spread
2
Is the mRNA Influenza Vaccine More Efficacious in Older Adults?
3
A Closer Look at IDSA/ESCMID 2026 Consensus Statements 6 and 7 on Staphylococcus aureus Bacteremia
4
CDC Updates Report on Antimicrobial Resistance
5